Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech Republic

NCT06955793 | Unknown

• 2 other identifiers: TAK-881 EAPTAK-881-3002 PIDD EAP
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This study will provide access to TAK-881 for participants with PIDD who have completed study TAK-881-3002 \[NCT06076642\], who continue to derive clinical benefit from maintenance treatment with TAK-881 and wish to continue this treatment. All participants will receive TAK-881 as subcutaneous (SC) injection using a qualified medical device (Koru 24 G HIgH Flo Subcutaneous Safety Needle Set) that will be individualized for each participant, at the treating physician's discretion and dependent on serum IgG trough level and clinical response. Participants will continue treatment until the benefit-risk no longer favors the participant or TAK-881 becomes commercially available in the United States (U.S.) and Czech Republic (the device is approved), the participant chooses to discontinue treatment, or the program is discontinued by the sponsor.

Conditions

Primary Immunodeficiency Diseases (PIDD)

Keywords

Drug Therapy

Interventions

TAK-881 BIOLOGICAL

Participants will receive SC infusion of TAK-881.

Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)

SC Investigational Needle Sets DEVICE

The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant has PIDD and has completed the end-of-study visit of Study TAK-881-3002.
• Participant is demonstrating continued benefit from TAK-881 for the treatment of PIDD in the opinion of the treating physician.
• Participant, or (in the case of minors) legally designated representative(s) is/are informed of the nature of this program and can provide written informed consent/assent (if applicable).
• Participant does not have any condition, including laboratory test result, that in the opinion of the treating physician may compromise the participant's safety.
• Participant does not have a known hypersensitivity to TAK-881 or its components.

You may not qualify if:

• Participant has potential to become pregnant and the participant does not agree to employ a highly effective form of contraception for the duration of the program.
• Participant is pregnant or lactating or intends to become pregnant or begin lactating during the program.

Sponsors & Collaborators

• Takeda: lead

Related Links

• To obtain more information on the study, click here/on this link

MeSH Terms

Conditions

Primary Immunodeficiency Diseases

Interventions

gamma-Globulins; Solutions

Condition Hierarchy (Ancestors)

Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Pharmaceutical Preparations

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Central Study Contacts

Takeda Contact

CONTACT

+1-877-825-3327; medinfoUS@takeda.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2025
• First Posted: May 2, 2025
• Last Updated: July 15, 2026

Record last verified: 2026-07